# Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant

> **NCT04425226** · NA · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 192 (estimated)

## Conditions studied

- Liver Transplant; Complications
- Hepatocellular Carcinoma Recurrent

## Interventions

- **DRUG:** Pembrolizumab Injection [Keytruda]
- **DRUG:** Lenvatinib Oral Product

## Key facts

- **NCT ID:** NCT04425226
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-06
- **Primary completion:** 2022-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2020-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425226, "Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04425226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*